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Acute respiratory manifestations of the abacavir hypersensitivity reaction
Abacavir, a carbocyclic nucleoside analogue reverse
transcriptase inhibitor, is used in combination with other
antiretroviral agents for the treatment of HIV-1 infection.
The major toxicity associated with therapy is a potentially
life-threatening hypersensitivity reaction occurring in
approximately 3–5% of patients, usually during the first
6 weeks of treatment, with a median time to onset of
8 days [1,2]. Clinical manifestations most frequently
include fever, rash, fatigue, gastrointestinal symptoms
such as nausea, vomiting, diarrhea and abdominal pain, and
respiratory symptoms such as pharyngitis, dyspnea and
cough. Although the described respiratory symptoms are
usually mild, we report here the case of a man who
developed acute, severe pneumonitis leading to acute
respiratory distress syndrome after 11 days of therapy with
abacavir.
The patient was a 57-year-old man with HIV who came
to medical attention in October 2002 as a result of
2 days of subjective fever, malaise and diarrhea.
Approximately 6 days before the onset of symptoms he
was seen in the infectious disease clinic, where his
antiretroviral regimen was changed from sustiva and
lamivudine–zidovudine to zidovudine, abacavir and
lopinavir–ritonavir. The change was prompted by a
drop in his CD4 cell count from 164 to 128 cells/ml over
the previous 3 months. Six days after the initiation of this
abacavir-containing regimen, he began to describe
profound fatigue, loose stools, along with episodic sweats
and chills, which worsened over the next 2 days,
requiring hospitalization. He denied dyspnea or cough at
that time and a chest X-ray was negative for acute disease
(Fig. 1a).
Within 72 h of admission, his initial symptoms were
followed by acute dyspnea, along with severe hypoxemia,
hemoptysis and new diffuse bilateral pulmonary infiltrates
on a chest X-ray (Fig. 1b). Abacavir was promptly
discontinued because of the suspicion of a hypersensi-
tivity drug reaction. The patient was then placed on
mechanical ventilation, underwent diagnostic broncho-
scopy, and was started on empiric antibiotic therapy for a
possible infectious etiology of symptoms. Transthoracic
echocardiography revealed normal left ventricular wall
motion and a normal ejection fraction. After 3 days of
abacavir discontinuation, the patient’s pulmonary status
improved dramatically, mechanical ventilation was
terminated, and the patient’s chest films showed almost
complete resolution of the infiltrative disease (Fig. 1c).
Electron microscopy of the bronchial washings revealed
Fig. 1. Chest radiographs (anteroposterior views) of the
patient. (a) On admission; (b) 11 days after the initiation of
abacavir therapy; and (c) 3 days after abacavir discontinuation.
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blood, mucus, benign respiratoryepithelium, macrophages
and neutrophils. No microorganisms or malignant cells
were seen. Cultures (blood and bronchial lavage fluid)
remained negative.
The hypersensitivity reaction described here highlights
the potential aggressive respiratory manifestations associ-
ated with the use of abacavir. Although the clinical
presentation of our patient at first suggested an infection
causing his symptoms, tests for infectious diseases were
negative, and in particular we witnessed a dramatic
improvement within 72 h after the withdrawal of
abacavir. Approximately 30% of life-threatening hyper-
sensitivity cases involve a respiratory symptom, the most
frequently reported of which are dyspnea, cough or
pharyngitis [3]. Our observation is remarkable because of
the unusual presentation of acute respiratory distress
syndrome as the manifestation of a hypersensitivity
reaction to abacavir.
Although the pathogenesis of abacavir hypersensitivity is
not entirely clear, data suggest that in certain individuals,
the creation of a chemically reactive metabolite leads to
immune activation and, ultimately, cellular damage [1].
The reactive intermediate acts as a hapten that covalently
binds to autologous proteins, creating an immunologi-
cally reactive metabolite–protein adduct. On interaction
of the metabolite–protein adduct with cells of the
immune system, the release of cytokines results in the
development of symptoms. The exact metabolite respon-
sible for hypersensitivity is unknown; however, the
generation of a carboxylate derivative after oxidation may
be implicated as the causative agent [4].
The key to appropriate clinical management is early and
accurate recognition of abacavir hypersensitivity to avoid
the symptoms described. The only established treatment
is discontinuation of the drug. Rechallenge with abacavir
after a hypersensitivity reaction typically results in the
recurrence of symptoms within hours, with the potential
to induce a more severe clinical syndrome with an
increased risk of life-threatening hypotension and death
[3]. Given the possibility of severe lung involvement,
clinicians need to monitor their patients on abacavir
closely and understand the need for the rapid disconti-
nuation of the drug, as this is the only established
treatment, if symptoms arise.
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Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis–HIV-co-infected
patients in resource-constrained settings
Tuberculosis is the most common serious opportunistic
infection associated with HIV infection in sub-Saharan
Africa, and a strong case has been made for integrating
tuberculosis and HIV care [1]. In those settings where
the tuberculosis and HIV epidemics converge, existing
tuberculosis programmes provide an opportunity for
efficiently identifying those HIV-infected patients who
are eligible for antiretroviral therapy (ART), as well as for
initiating this therapy in order to utilize the existing
tuberculosis directly observed therapy infrastructure. This
approach is, however, dependent on the availability of
effective, safe and affordable antiretroviral regimens that
are compatible with the standard treatments for tuber-
culosis, including rifampicin. As a result of cost considera-
tions, the widespread use of alternative rifamycins, such as
rifapentine or rifabutin, is not feasible in resource-
constrained settings.
Current guidelines, such as those from the US Depart-
ment of Health and Human Services, suggest that
regimens based on the non-nucleoside reverse transcrip-
tase inhibitor efavirenz be used as first-line choices in
patients receiving concomitant rifampicin [2]. Therapy
choices become far more difficult in the face of
treatment-limiting toxicities, virological failure or preg-
nancy. In these cases, a protease inhibitor-based regimen
is needed as nevirapine may not be an appropriate option
because of its interaction with rifampicin and additive
hepatic toxicity. The guidelines suggested the use of
ritonavir-boosted saquinavir [2]. Although the ability of
ritonavir to boost plasma concentrations of saquinavir is
well described, there is only limited evidence that this
combination is adequate to counteract the enzyme
induction caused by rifampicin and is clinically effective
[3,4]. The issue of a ‘Dear Health Care Provider’ letter by
Roche Pharmaceuticals on 7 February 2005 has now
caused considerable additional uncertainty [5]. The manu-
facturers have informed the US Food and Drug Adminis-
tration of problems experienced in a phase I, randomized,
open-label, multiple-dose clinical pharmacology study in
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healthy volunteers. Of 28 patients given rifampicin
600 mg once a day together with ritonavir 100 mg and
saquinavir 1000 mg twice a day, 11 (39.3%) had
developed significant hepatocellular toxicity during the
28-day study period. In the light of this evidence, the
continued use of this combination cannot be supported.
As a consequence, the US Food and Drug Administration
Advisory has now removed the only protease inhibitor-
containing regimen recommended for use concurrently
with rifampicin containing tuberculosis treatment, and
has thereby reduced the therapeutic options available for
those requiring ART beyond standard first-line therapy
options. In the absence of direct advice to the contrary,
two options are being explored that we feel to be
questionable. Some have argued that the exact doses of
ritonavir and saquinavir used in the pharmacokinetic
study (100 mg and 1000 mg, respectively) were different
from those used in practice (400 mg and 400 mg, given
twice a day), thus justifying thte continued use of this
combination. Others have argued that adding additional
ritonavir to co-formulated lopinavir–ritonavir would be
sufficient to overcome the hepatic enzyme induction
caused by concomitant rifampicin. However, in an open-
label, randomized trial of two such dosing regimens in
health volunteers, 12 out of 32 subjects withdrew from
the study [6]. For nine of these, the co-administration of
lopinavir–ritonavir and rifampicin was associated with
elevations in liver enzyme levels. The similarity to the
outcome of the saquinavir–ritonavir pharmacokinetic
study cannot be ignored. The remaining options are, thus,
either to switch to a triple nucleoside regimen or to cease
further antiretroviral therapy until the completion of the
rifampicin-containing tuberculosis treatment.
Until recently, the multitude of studies on alternative
treatment regimens has focused on the needs of the
developed world where ART has been widely available and
switching options are increasingly important. The Global
Fund Against AIDS, TB and Malaria, the WHO’s 3-by-5
programme, the US President’s Emergency Program For
AIDS Relief (PEPFAR) and local efforts are slowly
increasing access to ART in resource-constrained regions
such as sub-Saharan Africa. The newly described toxicity
of the rifampin, saquinavir, ritonavir regimen thus vividly
highlights the great need for research, particularly
pharmacokinetic studies, also to address the ARToptions
appropriate for resource-limited settings, and in particular,
in this instance, for co-administration with rifampicin-
containing tuberculosis treatment.
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Care should be taken when promoting microbicide use among sex workers who are able to use condoms
consistently: response to Smith et al. (2005)
In a recent paper in AIDS, Smith et al. [1] used
mathematical modelling to explore the issue of condom
migration, or ‘condom replacement’, on the potential
impact of microbicide use by female sex workers. Similar
to an earlier paper that we published [2], they developed a
static model of the risk of HIVacquisition, and used this to
Correspondence 303
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
obtain a threshold level of microbicide efficacy and use
required to offset condom replacement. Although there
are some differences in the mathematics used to formulate
the risk of HIV infection and the scenarios considered, in
most respects our two analyses yielded similar conclu-
sions. In particular, both concluded that condom
migration/replacement is not a substantial concern in
populations that have low levels of condom use (as did
Karmon et al. [3] in a similar analysis).
However, we are concerned that only the positive policy
conclusions are presented by Smith et al. [1] with regard to
condom replacement among sex workers: ‘For low/
moderate efficacy microbicides, the risk of HIV acquisi-
tion in FSWs will be reduced – even if complete condom
abandonment occurs – if prior condom use was low’.
This conclusion ignores the fact that, with proper
counselling and support, sex workers can achieve a high
rate of consistent condom use with their paying clients. A
recent review of surveys of sex workers in Asia generally
found that the median percentage reporting using a
condom with their clients in the last sex act was over 75%
[4,5]. There is also growing evidence across different
settings that, following intervention, sex workers
frequently achieve high levels of reported condom use
with their clients [6–11], with as many as 96% of male
military conscripts reporting using a condom at last
commercial sex in northern Thailand, for example [7].
Although there exist many sex worker populations who
have low levels of condom use with their clients [5,12–
15] (and many more that have not been studied), it is
important to acknowledge when considering micro-
bicide introduction scenarios that in some settings sex
workers have attained high levels of condom use.
Our analysis suggests that among groups of sex workers
with high levels of condom use, migration may be of
concern. We found that if sex workers originally used
condoms in over 53% of sex acts but abandoned condoms
altogether after the introduction of a 50% efficacious
microbicide, then the risk of HIV will increase even if
microbicides are used in every sex act [2]. If Smith et al. [1]
had considered higher levels of condom use, they would
have reached similar conclusions. For example, if Fig. 3
(b) had been extrapolated for higher levels of condom use,
then a threshold for a 50% efficacious microbicide can also
be seen [1]. From this, it appears that if sex workers had
originally used condoms in over 62% of sex acts but
abandoned condoms altogether after microbicide intro-
duction, then the risk of HIV will increase even if
microbicides are used in every sex act.
Our analysis also showed that if a microbicide of 50%
efficacy against HIVand sexually transmitted infections is
used in 50% of sex acts not protected by condoms then
high-consistency condom users (who use condoms in
90% of sex acts) could only reduce condom use to 86%
without increasing the risk of HIV [2]. However, this
‘high-consistency condom-user’ scenario was not dis-
cussed in the paper by Smith et al. [1].
The papers highlight the fact that further research is
needed to explore the issue of microbicide introduction
to sex workers. If women are able consistently to
negotiate condom use with their clients, both models
suggest that there may be risks associated with micro-
bicide introduction if it weakens women’s ability or
resolve to negotiate condom use. At the same time, this
result should not be used to withhold or limit the ability of
sex workers to access microbicides [16]. Clearly, there is
an urgent need for microbicides, to provide additional
protection to the many sex workers who are unable to
negotiate consistent condom use with their clients [5,12–
15], and to the many more who cannot use condoms in
their non-commercial relationships (despite achieving
high levels of use with clients) [4,5,9,11,17–19]. Instead,
such studies raise important programmatic challenges
about how best to promote microbicide use in a way that
does not undermine consistent condom use, recognizing
that there are small margins for error. For, although
mathematics can provide a quantification of the risks and
benefits, operational and social science research is needed
to identify how best to respond.
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Syphilis does not seem to involve virological and immunological course of concurrent HIV disease
In their interesting report, Buchacz and coworkers [1]
claim that novel syphilis infection is significantly linked to
an increase in viraemia and a drop in the CD4 lymphocyte
count, in their series of 52 HIV-infected men with
primary of secondary syphilis, but an antiretroviral treat-
ment rate limited to 58% of cases. Although statistically
significant or tending to statistical significance, the mean
variations in log10 HIV-RNA copies/ml observed before
and after syphilis were limited to a very restricted range,
from þ0.22 to 0.10, and the modification of the mean
absolute CD4 cell count ranged from62 toþ33 cells/ml,
respectively, before and after the concurrent syphilitic
infection [1]. These limited variations in laboratory data
are known to be of nearly negligible clinical value,
especially when considering the retrospective, non-
controlled study design, laboratory data evaluated by
different hospital facilities, and the natural evolution
of HIV disease, particularly when a substantial rate of
affected patients (42%) did not take advantage of anti-
retroviral drugs [1], and for the remaining 52% of patients
detailed data on HAART administration and efficacy are
lacking [1]. Therefore, we strongly believe that generali-
zations cannot be made on the grounds of the presented
data only.
After the recent concerns about the increase in sexually
transmitted diseases among HIV-infected individuals
[2–4], a prospective observational survey was undertaken
at our reference centre in a homogeneous cohort of over
1000 HIV-infected patients followed since the year 2001.
Thirty-eight patients (25 homo–bisexual men, and 13
heterosexuals) were identified as novel cases of syphilis
(secondary syphilis in 31 episodes), according to clinical
features and standardized laboratory testing, received
appropriate treatment, and were followed up for 18
consecutive months. Virological and immunological
testing were available for 36 patients (33 men and three
women, aged 29–58 years), including at least the
6 months preceding the diagnosis of syphilis, and the
9 months after disease treatment (Table 1). Only five out
of the evaluable 36 did not take any antiretroviral therapy,
but it was not indicated according to current international
guidelines [5]; all other subjects received various com-
binations of HAART containing at least three drugs, and
therapy was adjusted according to the present recom-
mendations in this field [5]. As summarized in Table 1, no
statistically significant trend of both virological and
immunological parameters was observed among the
HIV–syphilis co-infected patients, using either a plain
Student t-test, Wilcoxon rank sum test, or more sophis-
ticated statistical analysis.
Although the reciprocal relationship between syphilis and
HIV has not been extensively investigated from an
immunological and especially a virological point of view,
it is well known that the HIV-associated quantitative and
functional impairment of cell-mediated immune response,
could possibly affect the course of syphilis during HIV
disease, as suggested by appropriate animal models and
ex-vivo studies [6,7]. Impaired cellular immunity and
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blunted cytokine networks were clearly demonstrated
during the different stages of syphilis, leading to altered
migration and clearance mechanisms [7,8].
On the other hand, it is quite difficult to expect that a
non-opportunistic occurrence such as syphilis super-
infection may trigger potent pathogenetic pathways, able
to influence the course of HIV disease significantly,
especially when an effective control of immune recovery
can be obtained by HAART administration. The data
presented by Buchacz et al. [1] are also confusing, because
42% of their patients did not receive HAART, and the
authors did not explain who and why. The last, large
patient group might have experienced a greater worsen-
ing of their HIV disease course during and after syphilis
[1]. As a consequence, the entire evaluation of laboratory
markers of HIV progression in this case series becomes
absolutely unpredictable, and the perceived, minimal
variations in the mean CD4 lymphocyte count or mean
viral load cannot, in our opinion, be attributed to an
incidental syphilitic infection. Another relevant bias may
stem from the confounding definition of laboratory
examinations obtained ‘during’ syphilis, which included
determinations performed from 6 months before to 2
months after (an overall duration of up to 8 months
‘around’ the syphilis episode) [1]. In our series, a single
determination was made during the diagnosis and
treatment of syphilis, so that more affordable laboratory
analyses were performed during previous and subsequent
quarterly examinations.
Whereas we completely agree with the authors’ concerns
regarding the recent outbreaks of sexually transmitted
diseases in patients with HIV disease or exposed to HIV
[2–4], their arguments related to a possible, aspecific
activation of the immune system during concurrent
infections, which might be lead to enhanced viral
replication, were commonly claimed for the majority of
HIV-associated opportunistic disorders (i.e. cytomegalo-
virus, Epstein–Barr virus, tuberculosis, atypical myco-
bacteriosis, haematological malignancies, and so on), but
cannot be extrapolated to syphilis, because neither
updated literature data (all reported quotations are
10–15 years old), nor pathogenetic hypotheses are still
available. On the other hand, there is recent, mounting
evidence that syphilis is involved in immune dysfunction
[8,9], as well as in the apopotosis of lymphoid cells [9],
instead of their presumed activation.
Although healthcare givers have to take into careful
account all sexually transmitted diseases in patients having
HIV or at risk of being HIV infected [3,4], at this time
only extensive, prospective, case–control studies, matched
according to the use and effectiveness of antiretroviral
therapy, might answer some questions regarding the
eventual existence of bidirectional pathogenetic inter-
actions between HIV infection and syphilis.
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Table 1. Temporal trend of mean CD4 lymphocyte count and mean log10 HIV-RNA copies/ml in 36 evaluable HIV-infected patients who
developed a novel episode of syphilis since the year 2001.
6 months 3 months Diagnosis of syphilis þ3 months þ6 months þ9 months
Mean CD4 lymphocyte count (cells/ml) 555  132 573  141 589  120 573  133 598  139 587  131
Mean log10 HIV-RNA level (copies/ml) 3.1  0.8 3.3  0.4 3.2  0.7 3.5  0.8 3.2  0.5 3.3  0.7
Patients were followed before and after the occurrence of syphilis infection with at least quarterly laboratory examinations. No statistically
significant variation occurred through time (from 6 months before to 9 months after syphilis).
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Human placental transfer of atazanavir: a case report
Antiretroviral drugs, particularly protease inhibitors, cross
the placenta with variable efficiency. There are no
published data describing the human placental transfer of
atazanavir, but this has been documented in animal studies
(Bristol-Myers Squibb, unpublished data).
We describe a case of atazanavir use in pregnancy.
A 24-year-old Caucasian lady was diagnosed HIV-1
positive through antenatal screening at 14 weeks’ gesta-
tion with a baseline CD4 cell count of 22 cells/ml and
HIV viral load of 348 928 copies/ml. She commenced
highly active antiretroviral therapy with tenofovir,
lamivudine and nevirapine. Difficulties with tolerability
and adherence culminated in her commencing tenofovir,
lamivudine and boosted atazanavir at 30 weeks’ gestation
when her HIV viral load was 18 822 copies/ml. Two
weeks later she was well but jaundiced, with a bilirubin
level of 43 mmol/l, normal liver function and an HIV
viral load of 88 copies/ml. At delivery, the cord blood
atazanavir level was 362 ng/ml. A maternal atazanavir
level taken just before delivery was 1515 ng/ml with an
HIV viral load of less than 50 copies/ml. The baby was
clinically well, with a bilirubin level of 122 mmol/l at
birth not requiring intervention, and at 6 weeks had a
negative HIV DNA polymerase chain reaction and HIV
viral load.
Protease inhibitors are highly protein bound, and in
pregnancy increased maternal protein levels may reduce
free drug levels. In addition, high p-glycoprotein levels in
the placenta may limit placental drug transfer. This is
reflected in studies demonstrating the poor human
placental transfer of nelfinavir, ritonavir, saquinavir and
lopinavir [1]. The placental transfer of atazanavir has been
demonstrated in rat studies (Bristol-Myers Squibb,
unpublished data), but human data are lacking.
Atazanavir inhibits hepatic glucuronyl transferase, leading
to unconjugated hyperbilirubinemia in 22–47% of
patients taking atazanavir [2]. The degree of hyper-
bilirubinemia appears to be dose dependent, and work has
been done to establish an efficacious yet safe therapeutic
range for the drug [3]. If atazanavir crosses the placenta,
neonatal hyperbilirubinemia could result, with the risk of
neonatal neurotoxicity and kernicterus. On the other
hand, placental transfer of atazanavir may be of benefit in
terms of pre and postexposure prophylaxis for the infant.
This is the first report documenting the human placental
transfer of atazanavir. There were no significant clinical
sequelae for the infant. The drug was well tolerated and
adequate maternal levels were achieved at standard
dosing, resulting in a viral load decay of 2.33 log within
2 weeks.
Physicians prescribing atazanavir to women who are or
who may become pregnant need to be aware that
placental transfer does occur and that the baby should be
monitored appropriately. Further work is needed.
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Stopping antiretroviral therapy in ‘prematurely treated’ HIV-1-infected children with full viral supression
is safe
Unfortunately antiretroviral treatment (ART) cannot
eradicate HIV-1 and infected individuals are faced with
lifelong therapies. This problem is worse in vertically
infected children. In the long run, long therapies favour
reduced adherence to therapy, leading to incomplete viral
suppression and the emergence of drug-resistant viruses.
Furthermore, continued exposure to ART may produce
adverse effects, toxicities and metabolic complications
[1–3]. Several strategies have been explored to help in the
long-term management of HIV infection, among them
various types of ART interruptions in adults [4], and
recently in children with virological failure in a
retrospective study [5]. However, no longitudinal
studies regarding how ‘prematurely’ treated and well-
controlled children may respond to those strategies exist.
Many currently infected children have been treated
according to the 1996 guidelines that recommended early
treatment. However, the therapeutic management of
HIV infection in children has changed; current guidelines
(2004) are more cautious regarding the initiation of
ART.
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Our objective was to address the safety of stopping ART
in early treated children. For this, we have studied four
children in the context of a treatment interruption
programme guided by the CD4 T-lymphocyte counts.
Their pre-treatment characteristics would not meet the
current guidelines for starting therapy. The inclusion
criteria were: (i) stable highly active antiretroviral therapy
(HAART) for at least 6 months; (ii) CD4 cell count
greater than 25% and viral load below detectable limits
( 50 copies/ml) during the previous 12 months; despite
being grown-up children they were vertically infected
and the percentage CD4 cell count (%CD4) better
reflects the immunological status than the absolute
number; (iii) clinically asymptomatic and never having
had AIDS. The CD4 cell count and plasma HIV-RNA
level were measured monthly by flow cytometry and
Roche assay (50 copies/ml), respectively. HIV-related
diseases and adverse events were systematically monitored
during all follow-up. The criterion for re-introducing
HAART was the appearance of clinical symptoms or a
drop in the %CD4 of 15% or less.
Child 1, an 8-year-old girl who had been 6 years on ART
had a nadir (defined as the lowest %CD4 that each child
previously had) of 20.5% CD4, and was followed for 56
weeks. At entry, she had 25% (1345 cells/mm3) CD4,
which dropped to 17% (428 cells/mm3) during the first
4 weeks associated with a viral load increase (1150 copies/
ml). However, the percentage and absolute numbers of
CD4 cells increased in the next 4 weeks and always
remained higher than 20% (653 cells/mm3; Fig. 1a). The
viral load remained between less than 50 and
1630 copies/ml during follow-up (Fig. 1a).
Child 2 (16 years), who had been 10 years on ARTwith a
nadir of 25.8% CD4, was followed for 40 weeks. At entry
he had 33% (517 cells/mm3) CD4 and did not experience
a decrease, rather an increase in %CD4 and absolute
counts (Fig. 1b). The viral load remained between 50 and
3500 copies/ml during follow-up (Fig. 1b).
Child 3 (14 years), who had been 8 years on ARTwith a
nadir of 13% CD4, was followed for 80 weeks. At entry
he had 33% (856 cells/mm3) CD4. During the first
12 weeks his CD4 cell count decreased to 22.5%
(642 cells/mm3) associated with an increase in the viral
load (147 000 copies/ml). Although the CD4 cell count
never reached the initial figure it always remained greater
than 15% (> 300 cells/mm3; Fig. 1c). Although the viral
load ranged between 4230 and 147 000 copies/ml during
the follow-up, it was lower in the last 20 weeks (4230–
19 900 copies/ml) than during the first 36 weeks
(22 900–59 500 copies/ml; Fig. 1c).
Child 4 (15 years), who had been 10 years on ARTwith
a nadir of 13% CD4, was followed for 52 weeks. At
entry, he had 33.6% (1141 cells/mm3) CD4. During the
first 8 weeks without treatment his CD4 cell count
decreased to 25% (820 cells/mm3) and the viral load
increased (84 500 copies/ml). During the follow-up he
always had greater than 25% CD4 (> 505 cells/mm3;
Fig. 1d). Despite this, the viral load was always relatively
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Fig. 1. Evolution of the percentage of CD4 T lymphocytes, the percentage of CD8 T lymphocytes and log10 of the viral loads of
the four children in the study. (a) Child 1; (b) child 2; (c) child 3; and (d) child 4. –^– % CD4 T lymphocytes; –& – % CD8 T
lymphocytes; –~– log10 viral loads.
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high, ranging between 33 500 and 908 000 copies/ml
(Fig. 1d).
Some viral load rebound was observed during interrup-
tion, and although those values may seem high, children
normally have higher viral loads than adults, even after
HAART. Rebound of the viral load was more
pronounced in children 3 and 4, with CD4 cell nadirs
below 15% in comparison with those children who had
CD4 cell nadirs above that number, suggesting some
influence of previous CD4 cell numbers on the control
of viral replication. Nonetheless, all children always
presented with good %CD4 and remained asymptomatic
through all the interruption period. Also, the quality of
their lives was improved by being without HAART for
many weeks.
Our results demonstrate the safety of stopping ART in
HIV-infected children (prematurely treated according to
current guidelines). Those results are consistent with
previous reports in HIV-infected adults. Moreover,
children have a more functional thymus than adults,
which may allow a better recovery of their immune
system and they probably respond better to treatment
interruptions.
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What do HIV-infected patients become after an opportunistic infection?
Although antiretroviral therapy has demonstrated its
effectiveness [1,2] many patients are still admitted to
hospital as a result of an AIDS-defining opportunistic
infection (mainly toxoplasmosis and Pneumocystis carinii
pneumonia). Several studies [3–5] have underlined the
fact that over 50% of deaths in HIV-infected patients are
currently related to such AIDS-defining infections, and of
these latecomers 13% die within 2.5 years in spite of the
initiation of adequate antiretroviral therapy. However,
few studies have focused on the epidemiological and
sociodemographic characteristics of these patients. The
objective of this survey was to study survival among
patients presenting with an opportunistic infection in the
era of highly active antiretroviral therapy (HAART) and
to identify predictive factors for mortality.
We analysed epidemiological, clinical and biological
characteristics of all HIV-infected patients admitted to
hospital for an AIDS-defining opportunistic infection in
the Nice University Hospital and the district hospitals of
Fréjus and Cannes between January 1997 and January
1999. Patients were asked to complete a questionnaire
during a face-to-face interview at the end of their hospital
stay. Questions included sociodemographic data (circum-
stances of HIV screening and subsequent medical follow-
up) and details of treatment [6]. The same questionnaire
was submitted to patients 30 months after the diagnosis of
the inaugural opportunistic infection.
For patients lost to follow-up, we questioned official
registries at their place of birth to find out whether any
deaths had been registered.
Statistical analysis was conducted using SPSS software.
Chi-square and non-parametric Kruskall–Wallis test
results are given with a 5% level of significance. Survival
rates were calculated using Kaplan–Meier curves.
Eighty-one HIV-infected patients were included in this
study. Among these, 26 (32%) were unaware of their
HIV-positive status and therefore discovered this upon
admission to hospital (group 1); and 25 patients (31%)
knew they were infected but had received no care before
diagnosis (group 2); 30 patients (37%) had already had one
or several irregular contacts with the healthcare system
before diagnosis (group 3). There was no statistically
significant difference for the median CD4 T-cell count
and viral load between the three groups (CD4 T-cell
counts 50, 65 and 60 cells/mm3 and viral loads 5.5, 5.5
and 5.1 log copies/ml for groups 1, 2 and 3, respectively).
There was a larger proportion of intravenous drug users
(IVDU) in group 3 (53% versus 18% group 1; and 20%
group 2; P < 0.05). After a mean delay of 30 months
(range 7–60 months) after the diagnosis of opportunistic
infection, 20 of the 81 patients had died: four patients in
group 1, [one cytomegalovirus infection, one laryngeal
cancer, one HIV-related encephalopathy, one hepatitis C
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virus (HCV) infection], three in group 2 (two P. carinii
infections, one Hodgkin’s disease), and 13 in group 3
(three HIV-related wasting syndrome, one P. carinii
infection, one HIV-related encephalopathy, four HCV
infections, one suicide, and three of unknown cause). The
risk of death was significantly higher in group 3 than in
groups 1 and 2 (Fig. 1, log-rank test P ¼ 0.0012). Among
the 61 patients remaining alive at month 30, the course
was favourable in terms of clinical condition (normal
Karnofski score in all patients by the end of the year after
diagnosis, no recurrence of opportunistic infection), viral
load (in 80% of patients the viral load was below
400 copies/ml, regardless of group) and immunological
markers [DCD4 T-cell count þ 279 (group 1), þ 240
(group 2) and þ 183 (group 3)]. Our results are in
accordance with those described in other recent studies
[7,8].
Our study suggests that in the era of HAART, among
patients who present with an opportunistic infection in
the context of severe immune depression (CD4 T-cell
count < 200 cells/ml), non-adherent patients have a
higher mortality risk than patients in whom care is
delayed because of a lack of screening or a complete lack
of previous follow-up. The latter already have a higher
risk of dying than patients who benefit from medical
follow-up sooner, because the risk is 16-fold higher
during the first 6 months and fourfold higher within the
following 3 years [9].
Our results are in line with those of other studies [10,11],
in which non-adherence was shown to multiply the risk
of death by four to sixfold. Irregular follow-up generates
difficulties in adherence to antiretroviral treatment, with
well-known clinical, virological and immunological
consequences [12]. However, it also complicates surveil-
lance of the immune status and identification of any
requirement for prophylactic treatment.
The proportion of IVDU was higher in group 3 than in
the other groups in our study. The fact that IDVU were
more often in a precarious professional situation [13]
would suggest personal difficulties in complying with
regular treatment and follow-up schedules in relation
to overwhelming socioeconomic concerns. Moreover,
deaths related to HCV infection are more frequent in
group 3, which reflects a larger proportion of co-infected
patients in this group. It has recently been suggested that
early treatment initiation with HAART could slow the
progression of hepatic fibrosis resulting from HCV
infection [14]. However HCV infection cannot solely
explain the high mortality rate observed in this group; the
difference in mortality between the three groups remains
significant (P ¼ 0.01) even when HCV-related deaths
are excluded.
Irregular care thus appears to be an essential feature,
which should be a cause of concern before opportunistic
infections arise. This makes adherence reinforcement
strategies a matter of urgency, particularly at certain key
points during the course of treatment: reluctance upon
initial treatment prescription, the prospect of prolonged
and highly demanding treatment regimens, major side-
effects. . .. During these critical situations, discontinua-
tion of care might be avoided by an improved patient–
physician relationship and by a multidisciplinary approach
(treatment adherence counsellors, health educators,
psychologists, social workers. . .). Finally, improving
networking among the various medical and non-medical
facilities would ease the re-integration of patients into an
adequate care-providing framework.
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Fig. 1. Survival curve. The risk of death is significantly higher
in G3 (non-compliant patients or irregular follow-up) than in
G1 (non tested patients prior to admission) and G2 (patients
tested but no follow-up). Non-compliant patients;
patients with no follow-up; non tested
patients.
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Response to: ‘Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected
patients’
We appreciate the comments from Coll and Alonso-
Villaverde. As they appropriately point out, there are
many reasons why the literature is not uniformly
consistent with regard to the association between HIV
infection, antiretroviral therapy and atherosclerosis.
However, on the basis of the extensive data that exists
in the area of atherosclerosis imaging, particularly with
the intima-media thickness (IMT) endpoint, it is unlikely
that the methodology we used for assessing carotid IMT is
the major explanation for the differences among studies.
Studies such as ours that have carefully controlled for
known cardiovascular risk factors tend to find no
association between HIV status and atherosclerosis.
The matched design of our study was the first to
control prospectively for major cardiovascular risk factors.
We acknowledged in our discussion that the patients
included in our study as a group may have been at a lower
risk of atherosclerosis than those included in other
reports; none had a family history of premature coronary
heart disease, diabetes, or previous cardiovascular disease,
and only 22% were current smokers. This is a new area of
investigation and all possibilities need to be determined,
including potential differences in the atherothrombotic
clinical event with only marginally detectable differences
in atherosclerosis. Our study has recently concluded 96
weeks’ of follow-up. As we proceed with the final analysis
of our study, we will examine the differences among
groups in the rate of progression of carotid IMT. The
progression of subclinical atherosclerosis among the
different groups of participants may be more revealing
than discerning differences cross-sectionally. As concerns
the issues surrounding the use of protease inhibitors and
atherosclerosis, it is imperative that this relationship is well
understood and that prospective studies are conducted
before public health statements are made about whether
these agents are atherogenic, because these are evidence-
based life-saving medications for patients with HIV
infection.
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A case of HIV-associated fever of unknown origin: deficit of IL-1b antagonistic activity and resolution with
monocyte–granulocyte apheresis
Fever of unknown origin (FUO) is considered to be one
of the major diagnostic and therapeutic challenges in
medicine. We report here a case of HIV-associated FUO,
which displayed a selective deficit in IL-1b antagonistic
activity and was successfully treated with monocyte–
granulocyte cell apheresis (GCAP).
In August 2002, a 46-year-old male patient came to our
observation with a positive HIV test. In January 2003, he
began antiretroviral treatment with lopinavir, ritonavir,
zidovudine and lamivudine. His CD4 T-cell count was
281 cells/ml (14.8%) and his HIV-1 viral load was 27 719
RNA copies/ml before treatment. He achieved a
negative viral load (< 50 copies/ml) and 456 CD4 T
cells/ml by November 2003, and continues at the time of
writing to respond well to this same regimen. In February
2003, the patient began to report daily episodes of fever
characterized by two peaks, one late morning and the
second at nighttime. Both episodes were typically of 1 h
duration, with fever reaching 408C and followed by
asthenia, with difficulty executing daily activities. These
episodes persisted on a daily basis for 80 consecutive
weeks without interruption. The patient reported a
history of similar unexplained febrile episodes in his early
20s, which resolved spontaneously. To identify the cause
of the fever the patient was subjected to extensive clinical
and laboratory analysis, which failed to provide any
evidence of concomitant infectious (human T-cell
leukaemia/lymphoma virus type II, hepatitis C virus,
hepatitis B virus, human herpesvirus 8, Epstein–Barr
virus, cytomegalovirus, Leishmania, Brucella, Plasmodium
malariae, Mycobacterium tuberculosis, Borrelia Burgdorferi),
non-infectious inflammatory (rheumatoid factor, anti-
bodies specific for nucleic acids, endomisium, platelets),
or neoplastic diseases (total body computed tomography,
scintigraphy with labelled leukocytes, positron emission
tomography, colonscopy). Additional investigations
included abdomen and heart ultrasound scan, chest X-
ray, brain magnetic resonance imaging and bone marrow
biopsy. On the basis of this we classified the fever as HIV-
associated FUO [1].
TNF-a and IL-1b are pyrogenic cytokines that have been
suggested to play a role in FUO [2,3]. We measured their
levels in plasma samples collected at regular intervals
during the febrile episodes. All samples had very low or
undetectable levels of TNF-a. In contrast, the levels of
IL-1b were higher compared to those of a panel of 14
healthy donors (Fig. 1a). We then measured the IL-1
receptor antagonist (IL-1ra) and the decoy soluble
receptor II (IL-1sRII). IL-1ra and IL-1sRII are two
molecules that counteract IL-1b activity, the first by
binding with high affinity to the IL-1b receptor I, and the
second by binding to IL-1b and thereby preventing
binding to its receptor [3]. The levels of IL-1ra were
comparable to those of controls, whereas the IL-1 sRII
levels were significantly lower (Fig. 1a). These data
suggested that the patient had developed a selective deficit
in IL-1sRII activity.
As both TNF-a and IL-1b are monocyte-derived
cytokines, we subjected the patient, after signature of
an informed consent form, to six consecutive weekly
GCAP following a protocol already established in our





















8 16 24 32 70 100
Days from 1° GCAP


























HD HD HDPt Pt Pt
Fig. 1. Effects of monocyte–granulocyte cell apheresis on cytokines levels and body temperature. (a) Plasma levels of IL-1b, IL-1
receptor antagonist (IL-1ra) and the decoy soluble receptor II (IL-1 sRII) in 14 healthy donors (HD) and 11 patient samples (Pt)
collected during the febrile episodes. The horizon lines indicate mean values. (b) Body temperature of patient monitored on
different days after first monocyte–granulocyte cell apheresis (GCAP). The arrows indicate the day of execution of GCAP. (c)
Patient’s plasma levels of IL-1sRII on different days after last GCAP.
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institute for HIV-infected patients [4–6]. GCAP was
performed using an adsorptive type extracorporeal device
(Adacolumn, JIMRO, Takasaki, Japan). The device
contains a mono-use polycarbonate column with a
capacity of approximately 335 ml, filled with 220 g of
cellulose acetate beads (carriers) of 2 mm diameter,
bathed in sterile saline. The device has been developed for
selective absorption of activated leukocytes by apheresis
and it specifically absorbs monocytes and granulocytes,
with lymphocytes remaining substantially untrapped.
Previous studies have shown that GCAP can have several
immunomodulatory effects, including changes in cyto-
kine production and the regulation of leukocyte homing
receptors [6,7]. Each GCAP session was of 1 h duration.
We monitored body temperature at regular intervals
during and after GCAP (Fig. 1b). At day 8, corresponding
to the second GCAP, there was no change in the fever
episodes, with the patient having the day and night peaks
of fever as reported during the past 2 years. After the third
GCAP (day 16), the day peak began to reduce in intensity
and gradually disappeared. At the fifth GCAP (day 32) the
night peak was reduced in intensity and then gradually
disappeared. Four weeks after the last GCAP the patient
became apyretic. After 8 months of follow-up he is still
apyretic without any pharmacological support. Interest-
ingly, his blood levels of IL-1sRII have begun to increase
since the last GCAP (Fig. 1c).
These data suggest that a deficit in IL-1b antagonistic
activity can be associated with FUO and that GCAP can
normalize body temperature, possibly restoring the
homeostasis of the IL-1b system.
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Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient
IL-2 is a potent stimulator of T-cell proliferation and
maturation, used as intermittent therapy of HIV-infected
patients in combination with antiretroviral treatment to
increase the CD4 T-cell count [1–5]. Acute IL-2 therapy
has a dose-dependent hepatotoxicity estimated at
between 20 and 33% of cases [1,4]. We report the case
of an HIV-infected patient who developed liver nodular
regenerative hyperplasia (NRH), revealed by anicteric
cholestasis and portal hypertension 33 months after the
beginning of six courses of IL-2 therapy and 2 months
after rechallenge.
A 65-year-old man, seropositive for HIV-1, was referred
to our liver unit in July 2003 for chronic anicteric
cholestasis. He had no history of illicite drug use, no viral
co-infection and no excessive alcohol consumption. HIV
infection discovered in 1995 was treated with azidothy-
midine monotherapy. In 1996, treatment including
didanosine, lamivudine and saquinavir was started for a
low CD4 T-cell count (Fig. 1). In February 2000, with
the emergence of viral escape mutant, lamivudine was
stopped, abacavir and ritonavir were introduced. Viral
load dropped and remained definitely under the detection
level. He received six courses of IL-2 (4.5 MIU twice a
day, subcutaneously) for 5 days, stopped in September
2001 for adverse events (’flu-like syndrome, asthenia,
rash). He progressively developed an anicteric cholestasis.
In July 2003, a first liver biopsy showed mild portal
fibrosis without inflammation. Sinusoids were enlarged in
the mediolobular region. IL-2 therapy was re-introduced
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for a persistent low CD4 T-cell count. Two months later,
he a developed ascites, and the spleen was enlarged
without clinical signs of hepatic insufficiency. Endoscopy
revealed oesophageal varices (grade I–II). Liver function
tests, including albumin, prothrombin time and bilirubin,
remained within the normal range. Liver imaging showed
liver dysmorphy, without vascular obstruction, or liver
tumour. Transjugular liver biopsy with haemodynamic
evaluation showed portal hypertension (10 mmHg, N
< 4 mmHg), defined as the difference between wedge
hepatic venous pressure (18 mmHg) and free hepatic
pressure (4 mmHg) [6]. Liver histology showed no
cirrhosis, but modified liver architecture with atrophic
and hypertrophic hepatic cells, sinusoidal distension,
suggestive of NRH, confirmed by reticuline staining.
Eighteen months later the patient remained stable under
beta-blocker therapy.
Liver NRH is thought to result from occlusion of the
terminal branches of the hepatic arterioles and portal
veinules, secondary to endothelial cell damage [7]. In the
present case, the diagnosis of NRH was assessed by the
following considerations. First, the classic conditions
associated with liver NRH, including systemic and
vascular disorders, coagulopathies, myelo and lympho-
proliferative diseases, drug-induced endothelial toxicity
and diabetes [7], were ruled out. Second, our observation
clearly shows a temporal relationship between IL-2
therapy, the progressive development of an anicteric
cholestasis, and the appearance of portal hypertension
with oesophageal varices revealed by ascites 2 months
after IL-2 rechallenge. Third, the diagnosis of liver NRH
suggested by the presence of (grade I–II) oesophageal
varices despite a modest elevation of the hepatic venous
pressure gradient (below 12 mmHg), in the absence of
hepatocellular insufficiency was confirmed by sequential
liver biopsies showing the progressive appearance of
intrahepatic veinule abnormalities followed by remodel-
ling of liver architecture and fibrosis.
High dose of IL-2 induced severe systemic toxicity with a
capillary leakage syndrome characterized by a loss of
intravascular fluids, leading to generalized oedema and
haemodynamic instability and organ dysfunction [8].
Elevated transaminases and bilirubin are commonly
observed with subcutaneous IL-2 therapy (3–15 MIU/
day) [1,4]. However, hepatic tests are not fully described
in long-term follow-up studies [2]. Of note was the fact
that one series mentioned the occurrence of liver NRH
in a patient [3].
In our case, liver toxicity related to highly active
antiretroviral therapy could not be excluded, but does
not provide an explanation for portal hypertension in the
absence of cirrhosis. In animal models, pharmacological
doses of IL-2 ranging from 4  106 to 36  106 IU/kg














1996 2000 2001 2002 2003 2004 2005 Years



















Fig. 1. Antiretroviral treatment, hepatic tests, and CD4 cell count during the follow-up period. –—&–— Alanine aminoaspartate;
Alanine aminotransferase; gamma-glutamyl transferase; –—–— Alkaline phosphatase.
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per day induced vascular leak syndrome associated with
increased transaminases, hyperbilirubinemia, lymphocytic
infiltration in the livers of C57BL/6 mice as a con-
sequence of an increased production of TNF-a and
chemokines by activated Kupffer cells, increased adhesion
molecules by endothelial cells (interstitial cell adhesion
molecule 1, vascular cell adhesion molecule 1) [9], leading
to a decreased hepatic sinusoid blood flow [10,11].
Prolonged studies support a fibrogenic property of IL-2,
in rat with human recombinant IL-2 injection after 4
months [12], or in the schistosomia model in mice [13].
The diagnosis of liver NRH needs a careful examination
of liver tests, mainly anicteric cholestasis. Our observation
clearly shows a temporal relationship between IL-2
therapy and the occurrence of liver NRH, revealed by
portal hypertension in an HIV-infected patient.
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